Expedited pathways to antimicrobial agent approval by the U.S. Food and Drug Administration (FDA) have led to increased delays between drug approval and the availability of FDA-cleared antimicrobial susceptibility testing (AST) devices. Antimicrobial disks for use with disk diffusion testing are among the first AST devices available to clinical laboratories. However, many laboratories are reluctant to implement disk diffusion testing for a variety of reasons, including dwindling proficiency with this method, interruptions of the laboratory workflow, uncertainty surrounding the quality and reliability of disk diffusion tests, and a perceived need to report MIC values to clinicians. This minireview provides a report from the Clinical and Laboratory Standards Institute Methods Development and Standardization Working Group on the current standards and clinical utility of disk diffusion testing.
Humphries, R. M., Kircher, S., Ferrell, A., Krause, K. M., Malherbe, R., Hsiung, A., & Burnham, C. A. D. (2018, August 1). The continued value of disk diffusion for assessing antimicrobial susceptibility in clinical laboratories: Report from the clinical and laboratory standards institute methods development and standardization working group. Journal of Clinical Microbiology. American Society for Microbiology. https://doi.org/10.1128/JCM.00437-18